Tag Archives: healthcare

Wall Street Journal: The Assault on Drug Innovation

admin-ajax

Today, the Wall Street Journal published an editorial commenting on yesterday’s proposed plan by Secretary Hillary Clinton’s campaign to dramatically increase intrusive government regulation of our industry. BIO shared many of the concerns raised by this editorial, concerns which were noted in our statement yesterday. To put into perspective the potential consequences of that proposal, the editorial noted as an example that “Inside of a decade or two, metastatic cancer may become a chronic condition and chemotherapy a relic.” Breakthroughs Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , ,

Ezekiel Emanuel’s Flawed Solution

Jim Greenwood

In a New York Times op-ed today, Dr. Ezekiel Emanuel proposes “The Solution to Drug Prices.” The piece is problematic in many respects, but we agree with one of his primary contentions: in discussions about drug prices, value is the real issue. This point was nicely made in a recent Times piece, where it quoted Crystal Bedford, whose five year old daughter, Marley, suffers from a rare genetic disease, Rhizomelic Chondrodysplasia Punctata (RCPD). A treatment Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Rx Response Changes Name to Healthcare Ready

Healthcare Ready

Yesterday, Rx Response announced that its name will be changing to Healthcare Ready. For nearly nine years, Rx Response has helped protect patients’ continued access to medicines in more than 55 different disasters. The rationale for the name change is to better reflect its shifting mission of providing assistance in areas of healthcare outside of medicines and pharmacy. The group has gained significant experience and expertise in ‘coordinating the healthcare system and the public sector during disasters, Read More >

Health  |  Leave a comment  |  Email This Post
Tags: ,

Riding the Bull Market: What’s in Store for Biotech Dealmakers in 2015?

72263479

In many ways, 2014 was a record year for biopharma dealmaking, with $355 billion in total transactions, including $53 billion in partnering deals, $16.5 billion in venture investments and 133 IPOs. According to the 2015 Campbell Alliance Dealmakers’ Intentions Study, 2015 is shaping up to be the year of historic M&A in the biopharmaceutical sector, driven in part by greater access to capital. The partnering numbers at BIO 2015 further indicate that the appetite for Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

The Next Step: How Companies Build Successful Therapeutic Franchises from the Ground Up

Building a new franchise in a therapeutic from scratch poses a host of challenges, from whether to take the risk of entering a new area at all to whether and how to partner strategically with another company. It’s a challenge for both the biggest biopharma companies and emerging biotechs to evaluate how and when to enter new therapeutic areas and to try to ensure that their efforts will not only help patients in need but Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,